# Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

> **NCT02260986** · PHASE3 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 740 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Dupilumab
- **DRUG:** Placebo (for Dupilumab)
- **OTHER:** Topical Corticosteroid (TCS)

## Key facts

- **NCT ID:** NCT02260986
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2015-08
- **Final completion:** 2016-10
- **Target enrollment:** 740 (ACTUAL)
- **Last updated:** 2017-10-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02260986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02260986, "Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02260986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*